Rivastigmine for the treatment of dementia associated with Parkinson’s disease

Review

(2719) Views  (495) Full article downloads

Authors: Jennifer L Reingold, John C Morgan, Kapil D Sethi

Published Date May 2007 Volume 2007:3(6) Pages 775 - 783

DOI: http://dx.doi.org/10.2147/NDT.S1134

Jennifer L Reingold, John C Morgan, Kapil D Sethi

Movement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta, GA, USA

Abstract: Parkinson’s disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of patients over time. Parkinson’s disease dementia (PDD) is characterized by deficits in attention, executive and visuospatial function, and memory. The clinical diagnostic criteria and neuropathology surrounding PDD remain controversial with evidence of overlap among PDD, dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). Cortical cholinergic deficits are greater in PDD than in AD, and are well-correlated with the cognitive and neuropsychiatric dysfunction that occurs in PDD. Inhibition of acetylcholine metabolism is therefore a practical therapeutic strategy in PDD. This review examines current evidence for rivastigmine (a cholinesterase/butyrylcholinesterase inhibitor) treatment in PDD. In addition to its efficacy, we examine the safety profile, side effects, and cost effectiveness of rivastigmine in PDD. Rivastigmine provides modest benefit in PDD and further long-term studies are needed to determine the effectiveness and safety of rivastigmine over time. Tolerability is a problem for many PDD patients treated with rivastigmine. Future studies of rivastigmine in PDD should focus on pragmatic outcomes such as time to need for nursing home placement, pharmacoeconomic outcomes and simultaneous patient/caregiver quality of life assessments.

Keywords: Parkinson’s disease, dementia, rivastigmine, cholinesterase inhibitor

Readers of this article also read: